Wednesday - June 03, 2026

Category Archives: Science

DelveInsight Metastatic Breast Cancer Pipeline Drugs Report 2025: Drugs, Clinical Trials, Treatment Strategies, and Companies Shaping Future Therapies

DelveInsight’s “Metastatic Breast Cancer Pipeline Insights 2025” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the metastatic Breast Cancer pipeline landscape. It covers the Metastatic Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Glioma Pipeline Trends 2025: Novel Drugs, Clinical Trial Insights, Therapeutic Innovations, and Active Companies in Development

DelveInsight’s “Glioma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the glioma pipeline landscape. It covers the Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioma therapeutics … Continue reading →

JAK Inhibitor Treatment Landscape 2025: Pipeline Drugs, Clinical Trials Insights, Therapeutic Innovations, and Active Companies

DelveInsight’s “JAK Inhibitor Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the JAK Inhibitor pipeline landscape. It covers the JAK Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Glioblastoma Pipeline Drugs Report 2025: Promising Drugs, Advanced Treatment Approaches, Clinical Trials, and Leading Companies

DelveInsight’s “Glioblastoma Pipeline Insight, 2025” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Gthe lioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma pipeline … Continue reading →

Sleep Apnea Pipeline 2025: Emerging Drugs, Innovative Therapies, Ongoing Clinical Trials, and Key Companies Driving Next-Generation Treatments

DelveInsight’s, “Sleep Apnea Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 14+ pipeline drugs in Sleep Apnea pipeline landscape. It covers the Sleep Apnea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Hypertension Pipeline Drugs Report 2025: Unlocking Future Growth with Breakthrough Therapies in Development

DelveInsight’s, “Hypertension Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension pipeline therapeutics … Continue reading →

Microbiome Disease Pipeline Drugs Report 2025: Exploring the Emerging Therapies and Clinical Advancements Ahead

DelveInsight’s, “Microbiome Disease Pipeline Insight 2025” report provides comprehensive insights about 140+ companies and 180+ pipeline drugs in the Microbiome Disease pipeline landscape. It covers the Microbiome Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Gastrointestinal Stromal Tumors Pipeline Drugs Report 2025: Investigating Innovative Modalities Driving Transformative Treatments

DelveInsight’s, “Gastrointestinal Stromal Tumors Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the Gastrointestinal Stromal Tumors pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Dayhoff Technologies Ranked Best Microbiome Test

Scientists recognize Dayhoff as most accurate microbiome test using triple-sampling, immediate freezing, and research-grade shotgun metagenomics—setting new industry standard for consumer testing. DALLAS, TX – September 29, 2025 – Dayhoff Technologies, a clinical-grade microbiome testing company, today announced its consumer microbiome … Continue reading →